Holen Sie sich die Stockscreener-App
13.04
0.23%
-0.05
Handel nachbörslich:
13.06
0.02
+0.15%
Schlusskurs vom Vortag:
$13.09
Offen:
$13.2
24-Stunden-Volumen:
131.72K
Relative Volume:
0.12
Marktkapitalisierung:
$222.89M
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-5.4905
EPS:
-2.375
Netto-Cashflow:
$-502.70M
1W Leistung:
+0.85%
1M Leistung:
-3.18%
6M Leistung:
-81.75%
1J Leistung:
-57.29%
1-Tages-Spanne:
$12.95
$13.29
1-Wochen-Bereich:
$12.61
$13.29
52-Wochen-Spanne:
$11.95
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Firmenname
Atrium Therapeutics Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
13.03 | 223.91M | 10.73M | -455.74M | -502.70M | -2.375 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Atrium Therapeutics Inc Aktie (RNA) Neueste Nachrichten
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser
RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus
RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan
Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo
Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network
Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo
Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo
Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan
Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI
Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView
Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView
Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView
Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan
Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring the 91% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com
How Atrium Therapeutics (RNA) performance compares to expectations (Underperforming) 2026-05-08Earnings Miss Risk - Newser
What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà
Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan
[Form 4] Atrium Therapeutics, Inc. Insider Trading Activity - Stock Titan
Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan
Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option - Stock Titan
Atrium Therapeutics (RNA) CSO awarded 30,000 RSUs and 60,000 options - Stock Titan
Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Omdia: India’s smartphone shipments fell 5% in 1Q26 amid channel caution and pricing pressures - Weekly Voice
Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Finanzdaten der Atrium Therapeutics Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atrium Therapeutics Inc-Aktie (RNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):